01 / BORDERLINE SCORE
Should This Patient Start a Statin?
Combine Framingham, SCORE2, or QRISK3 with prednisone dose and carotid plaque overrides, then print a clinic handout.
Primary Consortium Evidence · Annals of the Rheumatic Diseases
Framingham Underestimates Rheumatoid Cardiac Risk by Up to One-Third
Pooled multivariable modeling across thirteen rheumatology cohorts confirms that standard general-population calculators systematically misclassify patients with sustained synovial inflammation, seropositive titers, and chronic glucocorticoid exposure.
Direct Clinical Conclusion
Uncorrected Framingham and ACC/AHA Pooled Cohort Equations miss roughly 28% to 34% of observed 10-year cardiovascular events in rheumatoid arthritis because active inflammation suppresses LDL cholesterol while accelerating arterial plaque. Apply the EULAR 1.5x multiplier (or use QRISK3 natively) and evaluate carotid duplex ultrasound whenever recalibrated 10-year risk enters the 5% to 10% borderline zone.
Primary evidence: Crowson et al., Ann Rheum Dis 2018 (PMID 28877868) and Crowson et al., PLOS ONE 2017.
Table 1: Standard Score Misclassification vs. Observed 10-Year MACE
| Population Equation | Observed / Predicted | RA Multiplier Applied | Impact on Statin Eligibility |
|---|---|---|---|
| Framingham Risk Score | Underpredicts 34% | 1.0x (Uncorrected) | Delays primary lipid therapy when DAS28 > 3.2 |
| ACC/AHA Pooled Cohort | Underpredicts 28% | None native | Requires manual inflammatory risk-enhancer override |
| QRISK3 (RA Weighted) | Calibrated 1.04 | Built-in RA hazard | Captures RA diagnosis and steroid exposure directly |
| EULAR + ATACC-RA Rule | Target 0.98 | 1.5x (Universal RA) | Reclassifies 11% of borderline cases into treat tier |
Plate 01: Carotid duplex screening uncovers subclinical plaque in up to 42% of reclassified intermediate-risk RA patients.
Outpatient Vascular Unit
Cumulative MACE Divergence (0-10 Years)
Observed ATACC-RA cardiovascular events diverge above Framingham predictions from Year 3 onward when active synovitis persists.
Resolve Your Clinical Question
Choose the Tool or Evidence Desk Matching Your Visit02 / CHOLESTEROL REBOUND
Why Did LDL Rise After Starting Treatment?
Simulate how CRP suppression under MTX, TNFi, and tocilizumab reverses inflammation-driven hypolipidemia.
03 / DRUG SELECTION
Is a JAK Inhibitor or Prednisone Safe Here?
Screen ORAL Surveillance age and smoking red flags and compare vascular hazard ratios across csDMARDs and biologics.
04 / ARCHIVAL CITATIONS
Verifying Manitoba, McGill, or PLOS Citations?
Access preserved investigator profiles (including Dr. Carol-Ann Hitchon) and full ATACC-RA / SURF-RA bibliography.